Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00337155
Status:
COMPLETED
Last Update Posted:
2023-11-02
First Post:
2006-06-13
Brief Title:
BAY88-8223 Dose Finding Study in Patients With HRPC
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Double Blind Randomised Dose Finding Repeat Dose Phase II Multicentre Study of Alpharadin for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223 Alpharadin in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| BC1-04 | OTHER | Algeta ASA | None |
| 2005-003680-22 | EUDRACT_NUMBER | None | None |